Last reviewed · How we verify

Spanish Lung Cancer Group — Portfolio Competitive Intelligence Brief

Spanish Lung Cancer Group pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Docetaxel/Cisplatin control Docetaxel/Cisplatin control phase 3 Chemotherapy combination (taxane + platinum agent) Microtubules (docetaxel); DNA (cisplatin) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Chinese Academy of Medical Sciences · 1 shared drug class
  3. Intergroupe Francophone de Cancerologie Thoracique · 1 shared drug class
  4. Jiangsu Cancer Institute & Hospital · 1 shared drug class
  5. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  6. Queensland Centre for Gynaecological Cancer · 1 shared drug class
  7. Samsung Medical Center · 1 shared drug class
  8. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Spanish Lung Cancer Group:

Cite this brief

Drug Landscape (2026). Spanish Lung Cancer Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/spanish-lung-cancer-group. Accessed 2026-05-18.

Related